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Objectives:  This study  aimed  to assess  the  disease  burden  and  economic  impacts  of human  nonpolio
enteroviruses  (NPEV)  and  enterovirus  A71  (EV-A71)  infection  in Taiwan.
Materials  and  methods:  We  included  children  under  ﬁve  years  old  (n =  983,127–1,118,649)  with  ICD-9-CM
codes  0740  (herpangina)  or 0743 (hand-foot-and-mouth  disease)  from  the  2006  to 2010  National  Health
Insurance  Database.  Severity  of enterovirus  infection  was  assessed  from  outpatient/emergency  visits,
hospitalization  (with/without  intensive  care  unit  [ICU]  admission),  infection  with  severe  complications,
and  death.  We  estimated  medical  costs  and  indirect  costs  from  the  societal  perspective.
Results: The  annual  rates  of NPEV  events  for  children  under  ﬁve  years  old  ranged  from  13.9%  to  38.4%,
of  which  5.1–8.8%  were  hospitalized.  EV-A71  accounted  for 7.8%  of all NPEV  medical  costs,  but  79.1% of
NPEV  ICU  costs.  Travel  costs  and  productivity  loss  of caregivers  were  $37.1  (range:  $24.5–$64.7)  million
per  year.  These  costs  were  not  higher  in  the  EV-A71  dominant  year ($34.4  million)  compared  with  those
in  the other  years.  Productivity  losses  resulting  from  premature  mortality  by  NPEV infection  were  $0.8
(range:  $0.0–$2.9)  million  per  year,  of which  96.3%  were  caused  by EV-A71.
Conclusions:  Diseases  associated  with NPEV  other  than  EV-A71  were  responsible  for most  of the medical
expenses.  In addition,  caregiver  productivity  loss by high  rates  of  NPEV  infection  impacted  the  society
much  more  than  medical  costs.  A  multi-valent  vaccine  that  includes  EV-A71  and  other  serotypes,  for
example  coxsackievirus  A16,  may  be beneﬁcial  to the  health  of  children  in Taiwan.
©  2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Nonpolio enteroviruses (NPEV) are associated with clinical
anifestations ranging from mild febrile illness to severe and
otentially fatal complications. Children under ﬁve years old are
he major sector of the affected population; however, most patients
uffer only mild diseases in the form of herpangina or hand, foot,
nd mouth disease (HFMD). A small percentage of patients rapidly
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develop neurological and systemic complications, especially in
cases of enterovirus A71 (EV-A71) [1].
EV-A71 was  ﬁrst identiﬁed in 1969 in California, USA [2], and
outbreaks have occurred in many countries, including Taiwan
[3–7]. The virus continued circulating in China, resulting in 82,486
severe cases and 2457 deaths from 2008 to 2013 [8]. Despite
considerable improvements in disease surveillance and case man-
agement for NPEV infection in areas of epidemic, the disease
burden of NPEV, particularly EV-A71, remains unclear. An EV-
A71 vaccine is expected to be available soon [9,10]; therefore, a
reevaluation of the epidemiology and economic consequences of
enterovirus infection could be of considerable beneﬁt to public
health decision-making [11]. This study sought to assess severity,
estimate disease burden and determine the impact of EV-A71 and
other NPEV infections on medical expenditures and other socioe-
conomic costs.
nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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. Materials and methods
This study has been approved by the Institutional Review Board
IRB) of Taiwan Centers for Disease Control (TCDC) in 2014 under
RB case number 103203.
.1. Surveillance
.1.1. Enterovirus laboratory surveillance
The laboratory surveillance system for enterovirus in Taiwan
as established after the 1998 outbreak of EV-A71. This sys-
em includes more than 250 sentinel clinics and hospitals located
ationwide. Two to ﬁve throat swabs were collected each week by
ach sentinel physician from patients with herpangina or HFMD
ithin three days of disease onset. These swabs were sent to con-
racted virological laboratories of eight academic medical centers
or virus isolation and typing.
.1.2. Reporting of enterovirus infection with severe
omplications
According to the Taiwan Communicable Disease Control Act,
nterovirus infection with severe complications is a category III
otiﬁable disease which must be reported within 24 h to the
ational Notiﬁable Disease Surveillance System (NNDSS). A suspect
ase is deﬁned as 1) a patient with herpangina or HFMD, accom-
anied by myoclonic jerks or encephalitis, acute ﬂaccid paralysis
AFP), acute hepatitis, acute myocarditis/cardiomyopathy, or car-
iopulmonary failure; or 2) myocarditis, hepatitis, encephalitis,
hrombocytopenia, multiple organ failure or viral sepsis syndrome
or infants under three months old. TCDC medical ofﬁcers ver-
fy case characteristics based on a case investigation report and
edical records. Conﬁrmed cases are suspect cases with a positive
nterovirus RT-PCR, viral culture, or EV-A71 IgM.
.2. Disease burden estimation
.2.1. National Health Insurance Database (NHID)
Approximately 99% of Taiwan residents are covered by the
ational Health Insurance; therefore, the NHID provides a highly
epresentative population-based medical utilization data [12].
hile national surveillance data are updated daily, there are delays
n NHID availability related to claims lag and adjudication. Disease
urden and economic impact estimations were based on the latest
vailable NHID (through 2010) at the time of this study.
The analyses of medical utilization included all children under
ve years old from 2006 to 2010 (n = 983,127–1,118,694). Within
his population, NPEV infections are identiﬁed in the NHID accord-
ng to the International Classiﬁcation of Diseases, Ninth Revision,
linical Modiﬁcation (ICD-9-CM) codes 0740 (herpangina) and
743 (HFMD). Children could be infected by different enterovirus
erotypes throughout their lives; therefore, an episode is counted
s a conﬁrmed incidence only in cases where the interval from the
ast NPEV visit exceeds one month.
.2.2. Disease severity
We  classiﬁed enterovirus episodes from NHID as outpatient
OPD), emergency department (ED) visit, and hospitalization, with
nd without intensive care unit (ICU) admission. In addition, NNDSS
ases with severe complications are followed for at least two  years
y linking to the NHID, using unique personal identiﬁers, and those
equiring ongoing antiepileptic prescriptions, rehabilitation, respi-
atory therapy, or home care after the ﬁrst six months of disease
nset are categorized as severe cases with unfavorable outcomes.
e also linked the NNDSS and the National Death Registry to iden-
ify unrecognized deaths that occurred after the ﬁrst six months.4 (2016) 974–980 975
The cause of death was  reviewed and veriﬁed by a TCDC medical
ofﬁcer (W.T.H.) with regard to its relevance to enterovirus infection.
2.2.3. Estimation of EV-A71 disease burden
It is practically impossible to collect clinical specimens from
every case and determine the serotype of every virus; therefore,
OPD, ED visits, and hospitalizations without ICU admissions caused
by EV-A71 was  estimated by multiplying the corresponding NHID
enterovirus episodes to the weekly proportion of EV-A71 among
enterovirus positive samples from the laboratory surveillance.
Clinical specimens of each case with severe complications and
death were tested and serotyped at national reference laboratories.
Cases of hospitalization with ICU admissions due to EV-A71 were
estimated according to the proportion of EV-A71 among conﬁrmed
severe cases.
2.3. Economic impact estimation
This study adopted a societal perspective in estimating the
economic impact of enterovirus infection. We therefore included
indirect costs as well as medical costs [13]. All amounts are pre-
sented in US dollars ($).
2.3.1. Calculation of medical expenditures
Medical expenditure for enterovirus infection was  calculated
using claims data from the NHID in accordance with the deﬁnitions
described in Section 2.2.1. We  included the registration fees, med-
ical expenditures paid by health insurance and copayments. The
registration fee for OPD and ED visits was respectively estimated at
$5 and $10 per visit. The total costs for registration were calculated
based on the standard described above and the number of visits
listed in the NHID. No information was available for the costs paid
out of pocket; however, this would be a relatively small sum due
to the fact that National Health Insurance covers almost all direct
costs [12].
2.3.2. Indirect cost estimation
In this study, indirect costs include travel costs to the medical
facility, productivity losses of the caregivers, and costs associ-
ated with the premature mortality of patients. Travel costs were
assumed to be $2 for each OPD visit and $4 for each day of hos-
pitalization (two caregivers in turn) based on the prices for public
transport in Taiwan (single fare: $0.5–$0.7, $0.2–$0.5 per unit if
beyond basic distance; children under six years old are free). The
cost of a trip to the ED was  assumed to be $10, taking into account
the cost of a taxi ride and the distance to the hospital.
Costs related to caregivers’ absences from work were deter-
mined by multiplying the number of days of missed work for
the provision of care to sick children by the daily mean earn-
ings in 2010 ($32.07), which was  equal to ($1211/month) × (12
months + 1.5 month bonus)] × labor force participation rate
(57.92%) × [1 − unemployment rate (5.21%)]/yearly working days
(280 days). These parameters are in accordance with the 2010
indices from National Statistics by Directorate-General of Budget,
Accounting and Statistics [14]. Basic information related to care-
givers and the average period of leave for patient care was  obtained
from a telephone survey with a sample size of 1242 adults by
the TCDC in July 2013. According to the survey, absenteeism for
caregivers averaged 4.9 days for each case without hospitalization.
Productivity losses of caregivers for hospitalized children were esti-
mated as the number of hospitalization days multiplied by daily
mean earnings in 2010.The human capital approach was  used to estimate productivity
losses from premature mortality [15]. First, the life expectancy of
each case at the age of death was  found in the Life Table published
by Ministry of the Interior [16]. The value of remaining lifetime
976 D.-P. Liu et al. / Vaccine 34 (2016) 974–980
Table  1
NPEV serotype distribution according to enterovirus laboratory surveillance, 2006-2014.
Year 2006 2007 2008 2009 2010 2011 2012 2013 2014 Trend
Serotype%
Coxsackie A 25.4 68.2 46.8 72.9 83.7 72.1 34.8 66.1 83.1
Coxsackie B 6.0 2.9 15.9 8.7 6.3 8.5 6.5 11.2 7.8
Echoviruses 7.7 8.5 2.4 4.0 3.7 1.3 4.4 4.8 5.0
EV-A71 0.05 0.6 26.4 2.6 1.9 10.9 46.4 1.6 0.1
Unknown serotype 60.8* 19.8 8.5 11.8 4.4 7.2 7.9 16.3 4.0
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* The proportion of NPEV isolates with unknown serotype was  higher in 2006, as
roductivity was estimated by summing up the yearly mean earn-
ngs over the expected lifespan, which was calculated similar to the
ethod for daily mean earnings described above, but with the 2010
ndices speciﬁc for various age groups throughout life. In addition,
he future values of productivity loss were discounted at a rate of
% [13,17].
.4. Statistics
The statistical package SAS 9.3 (SAS Institute Inc., Cary, NC) was
sed to analyze data.
. Results
.1. Surveillance
From 2006 to 2014, there were 1153–3698 NPEV isolates per
ear from laboratory surveillance (Table 1). Most of the circulating
iruses were coxsackie A viruses; an epidemic of EV-A71 occurred
very 3–4 years (Fig. 1). Two major epidemics occurred, dominated
y EV-A71 (2008) and coxsackievirus A16 (2010), respectively. An
utbreak of EV-A71 occurred in weeks 46–52 of 2011 and the virus
ontinued circulating until the end of 2012.
The number of cases with severe complications was higher in
V-A71 dominant years, particularly in 2008. From 2006 to 2014,
12 (91.6%) of the 559 cases with severe complications were caused
y EV-A71, followed by coxsackievirus A (coxsackievirus A2, A4, A5,
6, A10 and A16; 3.6%) and other NPEVs (coxsackievirus B1, B3, B4,
nd B5; echovirus 6, 11 and 30).
.2. Disease burden and severity
.2.1. Incidence and medical utilization
Among children under ﬁve years old, the number of NPEV
pisodes in the 2006–2010 NHID was 141,316 to 377,478 per year
annual incidence: 13.9–38.4%) (Table 2); of these, 9,823 to 133,461
pisodes were coded as HFMD (annual incidence: 0.9–13.6%). There
as an average of 1.3 episodes of NPEV infection per patient-year.
.2.2. Hospitalization
Among children who visited the OPD or ED, 5.1–8.8% were hos-
italized (Fig. 2A). Among the hospitalized, 0.7–3.0% required ICU
dmission, 0.1–1.5% developed severe complications (Fig. 2B), and
.03% died. The rate of hospitalization and ICU admission was the
ighest in 2008 (Table 2), with a relatively high proportion of ICU
nd severe cases among the hospitalized (3.0% vs. 0.7–1.3% in the
ther years) (Fig. 2B). The 2009 hospitalization rate was  comparable
o that of 2008 (8.8%) but with fewer severe cases.24 3289 2156 1400 1153
ed antisera for NPEV was available at Taiwan CDC at that time.
3.2.3. Cases with severe complications
Among 329 cases with severe complications from 2006 to 2010,
104 (31.6%) had unfavorable outcomes (Table 3). The rates of unfa-
vorable outcome were similar between EV-A71 and non-EV-A71
severe cases (31.3% vs. 34.4%, p = 0.71). Compared with other NPEV
serotypes, EV-A71 severe cases with unfavorable outcomes were
more likely to require home care, respiratory therapy, or rehabilita-
tion, but less likely to require antiepileptic prescription (p = 0.0017).
Twenty (95.2%) of the 21 deaths during the ﬁrst six months were
associated with EV-A71, and six additional EV-A71 severe cases
died during the period of six months to two  years of disease onset.
Among the 26 deaths, enterovirus infection was considered respon-
sible for the death of 25, with the exception of one Down syndrome
patient.
3.3. Economic impact
NPEV infection accounted for 1.1% to 3.7% of the annual national
health insurance expenditures among children under ﬁve years old
($526–$557 million, $475–$567 per capita) [18]. The average med-
ical cost for enterovirus infection in the ﬁrst six months of disease
onset (“acute phase”) was  $11.3 million per year (Table 4). Costs in
the year of the EV-A71 epidemic (2008) did not exceed those of the
coxsackievirus A16 epidemic (2010). The estimated medical costs
caused by EV-A71 varied by the year and contributed to only 7.8%
of all NPEV medical costs. Nonetheless, these costs accounted for
79.1% of all NPEV ICU costs.
Average travel costs and productivity losses by caregivers were
$37.1 million per year (Table 4). Costs in the EV-A71 dominant year
($34.4 million) did not exceed those in the other years because of
the enormous number of mild diseases associated with non-EV-
A71 serotypes. Estimated costs due to EV-A71 were $1.9 million
per year, which represents only 5.0% of all NPEV costs.
Total productivity losses resulting from premature mortality
of the 26 NPEV deaths, after the 3% discount, were $4.0 million
($0.8 million per year), of which $3.8 million (96.3%) were asso-
ciated with EV-A71 (Table 4). The productivity losses of patients
with unfavorable outcomes and their caregivers were not included
because each patient was  followed for only two  years in this study.
4. Discussion
Taiwan experienced an unprecedented outbreak of EV-A71 in
1998. This involved 405 severe cases, including the death of 78 chil-
dren [7]. Surveillance systems for enteroviruses were established
immediately after the outbreak. The diagnostic capabilities of the
laboratories and clinical administration have been well-established
for over a decade. Despite the fact that EV-A71 outbreaks occur
every 3–4 years, and no antiviral drugs are currently available, the
case-fatality rate in severe cases decreased from 19.3% (1998) to
D.-P. Liu et al. / Vaccine 34 (2016) 974–980 977
Fig. 1. Enterovirus infection in Taiwan over the period 2006 to 2014: (A) Virological Laboratory Surveillance; (B) National Health Insurance Database analysis: Emergency
department (ED) consultations; (C) Communicable Disease Reporting System for enterovirus Infection with Severe Complications.
Table 2
Medically-attended nonpolio enterovirus infection among children under 5 years old and its occurrence by disease severity (by episode).
Year 2006 2007 2008 2009 2010
Episode 155,700 209,127 197,425 141,316 377,478
Annual incidence* 13.9% 19.5% 19.0% 13.9% 38.4%
Hospitalization (%)† 7962 (5.1) 14,383 (6.9) 17,292 (8.8) 12,441 (8.8) 26,592 (7.0)
ICU  (per 100,000)† 68 (43.7) 100 (47.8) 511 (258.8) 167 (118.2) 245 (64.9)
Severe complications (per 100,000)† 11 (7.1) 12 (5.7) 261 (132.2) 29 (20.5) 16 (4.2)
Death  (per 100,000)† 0 (0.0) 4 (1.9) 14 (7.1) 2 (1.4) 0 (0.0)
* Denominator is the total population under 5 years of age in a given year.
† Denominator is the total number of medically-attended NPEV episodes.
978 D.-P. Liu et al. / Vaccine 34 (2016) 974–980
Fig. 2. Distribution of NPEV disease severity by episode, 2006–2010: (A) Hospitalization vs. outpatient (OPD) or emergency department (ED) visits only; (B) Severe cases,
patients requiring intensive care (ICU) vs. other forms of hospitalization.
Table 3
Outcomes of enterovirus cases with severe complications at 6 months and 2 years after onset, organized by virus serotype, 2006–2010 (N = 329).
EV-A71 (n = 297) Non-EV-A71 (n = 32)
Follow-up interval after onset 6 months 2 years 6 months 2 years
Recovered* 184 (62.0) 233 (78.5) 20 (62.5) 26 (81.3)
Died* 20 (6.7) 26 (8.8) 1 (3.1) 1 (3.1)
Unfavorable outcome* 93 (31.3) 38(12.8) 11 (34.4) 5 (15.6)
-Home care† 3 (3.2) 3 (7.9) 0 (0.0) 0 (0.0)
-Respiratory therapy† 35 (37.6) 9 (23.7) 3 (27.3) 1 (20.0)
-Rehabilitation† 68 (73.1) 27 (71.1) 5 (45.5) 2 (40.0)
-Antiepileptic prescription† 14 (15.1) 3 (7.9) 6 (54.5) 2 (40.0)
* Denominator is the total number of severe EV-A71 or non-EV-A71 cases.
† Denominator is the total number of severe EV-A71 or non-EV-A71 cases with unfavorable outcome at 6 months or 2 years after onset.
D.-P. Liu et al. / Vaccine 34 (2016) 974–980 979
Table  4
Economic impact of nonpolio enteroviruses comparing 2008 vs. 2010 (cost: million USD).
Year 2008 2010 2006–2010 average
Caused serotype All EV-A71 All EV-A71 All EV-A71 EV-A71 %
Cost  category (%) (%) (range)
Medical costs
- Acute phase 12.48 2.61 20.49 0.30 11.33 0.65 5.7%
(20.9) (1.5) (5.84–20.49) (0.02–2.61) (0.3–20.9%)
ICU 1.13 1.07  0.35 0.20 0.37 0.29 79.1%
(94.7) (57.3) (0.06–1.13) (0.01–1.07) (11.5–94.7%)
-  Unfavorable
outcomes*
1.02 1.01 0.09 0.09 0.28 0.25 91.5%
(99.5) (96.5) (0.08–1.02) (0.00–1.01) (0.5–99.5%)
Non-medical costs† 34.35 7.26 64.71 1.01 37.05 1.85 5.0%
(21.1) (1.6) (24.52–64.71) (0.02–7.26) (0.1–21.1%)
Productivity loss due to
premature mortality‡
2.90 2.90 0.15 0.15 0.79 0.76 96.3%
(100.0) (100.0) (0.00–2.90) (0.00–2.90) (67.7–100.0%)
Total  costs 50.75 13.35 (26.3) 85.44 1.55 (1.8) 49.45 3.51 7.1%
* Deﬁnition of cases with unfavorable outcomes: Please see Table 3. Each case was followed for 2 years after disease onset; i.e., the costs listed for 2008 cover the medical
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tosts  of caring for patients until the end of 2010.
† Non-medical costs include traveling fees and caregiver productivity losses.
‡ Deaths within 2 years of follow-up are also accounted for.
pproximately 5% (2006–2014). The mortality rate related to NPEV
nfection for children under ﬁve years old also decreased to 0–14
er million (median 2) during 2006–2014, compared with 4–48
er million (median 18) in 1998–2005 [19]. Delayed or inappro-
riate case management could affect prognosis of NPEV infection
1]; however, this was less likely a problem since 2006 after years
f clinical experience, healthcare professional training and health
ducation. Therefore, data collected during the period of this study
llow for a more solid estimate of disease burden.
Most cases of enterovirus infection result in only mild disease;
herefore, morbidity based on passive reporting was usually under-
stimated. Xing et al. [8] reported a HFMD incidence of 1.2 per 1000
erson-years, based on an enhanced national surveillance program
n China. Our study observed a much higher incidence (9–136
er 1000 person-years) from medical utilization data. Because
any patients with mild illness may  not seek medical care, our
esults may  represent only a small proportion of all symptomatic
PEV infections. In addition, we did not estimate the occurrence
f asymptomatic infections, which could be countered by sero-
revalence surveillance [20,21]. However, a further understanding
f epidemiology could provide parameters of greater accuracy for
odeling and the estimation of cost effectiveness with regard to
ontrol measures, such as school closures and vaccination [22].
Few studies on the economics of enteroviruses and EV-A71
nfection have been performed. One of the difﬁculties is under-
eporting of mild cases. In addition, it is impossible to clinically
ifferentiate EV-A71 cases from other NPEV infections. Lee et al.
23] developed a computer simulation to determine the potential
conomic value of an EV-A71 vaccine for children. The results sug-
est that a $50 or $75 vaccine for populations with infection risk
0.4% would be highly cost-effective even when vaccine efﬁcacy
s as low as 50%. Nevertheless, the study assumed that probabili-
ies of encephalitis (26.4%), pulmonary edema (10.0%), and aseptic
eningitis (5.1%) are relatively high; therefore, the disease burden
f EV-A71 infection may  be overestimated. This study, using NHID,
evealed that non-severe diseases accounted for the majority of
edical expenses and societal costs associated with non-EV-A71
PEV. Furthermore, because incidence of mild NPEV infection was
igher, the associated productivity losses by caregivers had greater
mpact on society than medical costs. Although EV-A71 causes a
igher number of severe complications and death, the number of
ases is small enough that the economic impact, even from societal
erspective, is negligible.
Several vaccines have recently been developed for EV-A71 and
he efﬁcacy/effectiveness results appear promising. Based on ourresults, the introduction of EV-A71 vaccine as a national program
in Taiwan would have only a limited impact on morbidity, hospi-
talization, and societal costs of NPEV infection. After the EV-A71
epidemic in 2008, physicians may  be more aware of severe cases
and have taken extra precautions. As a result, the 2009 epidemic
associated with a non-EV-A71 serotype was observed with a higher
proportion of hospitalization, but lower proportion of severe cases,
compared with those in 2008. Following the introduction of EV-
A71 vaccines, the attention on enterovirus infection may  wane due
to reductions in disease severity and number of fatalities associ-
ated with NPEV. In addition, medical expenditures and caregiver
productivity losses associated with the pre-emptive hospitalization
of at-risk patients may  also decrease, which could make the vac-
cine more cost-effective. Continued monitoring for behavior and
opinions of parents and physicians following the introduction of
the EV-A71 vaccine would be needed to support this hypothesis.
An EV-A71 vaccination, based on the current results, would relieve
only a small proportion of the economic impact of NPEV infection
by preventing most cases with severe complications, unfavorable
outcomes, and deaths. Therefore, developing a multivalent vaccine
that includes EV-A71 and other common serotypes (e.g., coxsack-
ievirus A16) may  be considered.
Enteroviruses are associated with various clinical symptoms,
including respiratory illness, febrile rash illness, neurologic illness,
and recently gastrointestinal illness such as diarrhea [24]. Because
herpangina and HFMD cover only a subset of diseases caused by
enteroviruses, the actual disease burden should be much higher
than that was reported in this study. Another limitation of this study
is that the costs of purchasing nonmedical equipment associated
with interventions or outcomes were not calculated. In addition,
the follow-up period was  only two  years; this may  result in an
underestimation of disease burden, and productivity losses related
to patients with unfavorable outcomes and their caregivers were
not estimated. Further studies regarding the cost-effectiveness of
vaccines will require evaluation of the long-term prognosis of cases.
5. Conclusions
This study revealed a high burden of NPEV medical events, and
that EV-A71 among children under ﬁve years old accounted for
most of the severe cases. High caregiver productivity losses had
a more pronounced impact on society than medical costs. These
results suggest that a multivalent vaccine that includes EV-A71
and additional NPEV serotypes may  be beneﬁcial to the health of
children in Taiwan.
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